Aptevo Therapeutics Inc. – NASDAQ:APVO
Aptevo Therapeutics stock price today
Aptevo Therapeutics stock price monthly change
Aptevo Therapeutics stock price quarterly change
Aptevo Therapeutics stock price yearly change
Aptevo Therapeutics key metrics
Market Cap | 2.22M |
Enterprise value | N/A |
P/E | 1.56 |
EV/Sales | -1.14 |
EV/EBITDA | -0.12 |
Price/Sales | 3.06 |
Price/Book | 0.53 |
PEG ratio | 0.01 |
EPS | -98.07 |
Revenue | N/A |
EBITDA | -27.61M |
Income | -27.01M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 877.55% |
Oper. margin | -1342.77% |
Gross margin | 0% |
EBIT margin | -1342.77% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAptevo Therapeutics stock price history
Aptevo Therapeutics stock forecast
Aptevo Therapeutics financial statements
| Jun 2023 | 0 | -7.94M | |
|---|---|---|---|
| Sep 2023 | 0 | -6.33M | |
| Dec 2023 | 902K | -5.90M | -654.43% |
| Mar 2024 | 0 | -6.83M |
| 2025 | 0 | -31.29M | |
|---|---|---|---|
| 2026 | 13.21M | -18.57M | -140.51% |
| 2027 | 57.93M | 528.31K | 0.91% |
| 2028 | 77.14M | 895.35K | 1.16% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 28912000 | 12.65M | 43.78% |
|---|---|---|---|
| Sep 2023 | 27129000 | 12.41M | 45.75% |
| Dec 2023 | 24842000 | 12.62M | 50.81% |
| Mar 2024 | 17629000 | 11.52M | 65.38% |
| Jun 2023 | -4.80M | 0 | 481K |
|---|---|---|---|
| Sep 2023 | -6.24M | 0 | 4.34M |
| Dec 2023 | -5.25M | 0 | 3.04M |
| Mar 2024 | -6.65M | 0 | -3K |
Aptevo Therapeutics alternative data
| Aug 2023 | 45 |
|---|---|
| Sep 2023 | 45 |
| Oct 2023 | 45 |
| Nov 2023 | 45 |
| Dec 2023 | 45 |
| Jan 2024 | 45 |
| Feb 2024 | 45 |
| Mar 2024 | 40 |
| Apr 2024 | 40 |
| May 2024 | 40 |
| Jun 2024 | 40 |
| Jul 2024 | 40 |
Aptevo Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Nov 2021 | 0 | 1760000 |
-
What's the price of Aptevo Therapeutics stock today?
One share of Aptevo Therapeutics stock can currently be purchased for approximately $1.96.
-
When is Aptevo Therapeutics's next earnings date?
Unfortunately, Aptevo Therapeutics's (APVO) next earnings date is currently unknown.
-
Does Aptevo Therapeutics pay dividends?
No, Aptevo Therapeutics does not pay dividends.
-
How much money does Aptevo Therapeutics make?
Aptevo Therapeutics has a market capitalization of 2.22M.
-
What is Aptevo Therapeutics's stock symbol?
Aptevo Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "APVO".
-
What is Aptevo Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aptevo Therapeutics?
Shares of Aptevo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aptevo Therapeutics's key executives?
Aptevo Therapeutics's management team includes the following people:
- Mr. Marvin L. White Pres, Chief Executive Officer & Director(age: 63, pay: $859,500)
- Mr. Jeffrey G. Lamothe Senior Vice President, Chief Financial Officer & Treasurer(age: 59, pay: $564,870)
-
How many employees does Aptevo Therapeutics have?
As Jul 2024, Aptevo Therapeutics employs 40 workers.
-
When Aptevo Therapeutics went public?
Aptevo Therapeutics Inc. is publicly traded company for more then 9 years since IPO on 20 Jul 2016.
-
What is Aptevo Therapeutics's official website?
The official website for Aptevo Therapeutics is aptevotherapeutics.com.
-
Where are Aptevo Therapeutics's headquarters?
Aptevo Therapeutics is headquartered at 2401 4th Avenue, Seattle, WA.
-
How can i contact Aptevo Therapeutics?
Aptevo Therapeutics's mailing address is 2401 4th Avenue, Seattle, WA and company can be reached via phone at +20 68 380500.
Aptevo Therapeutics company profile:
Aptevo Therapeutics Inc.
aptevotherapeutics.comNASDAQ
40
Biotechnology
Healthcare
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Seattle, WA 98121
CIK: 0001671584
ISIN: US03835L2079
CUSIP: 03835L207
